434 related articles for article (PubMed ID: 30098594)
1. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885
[TBL] [Abstract][Full Text] [Related]
3. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
4. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis.
Kap YS; Bauer J; Driel Nv; Bleeker WK; Parren PW; Kooi EJ; Geurts JJ; Laman JD; Craigen JL; Blezer E; 't Hart BA
J Neuropathol Exp Neurol; 2011 Nov; 70(11):992-1005. PubMed ID: 22002426
[TBL] [Abstract][Full Text] [Related]
6. Early axonal damage and progressive myelin pathology define the kinetics of CNS histopathology in a mouse model of multiple sclerosis.
Recks MS; Stormanns ER; Bader J; Arnhold S; Addicks K; Kuerten S
Clin Immunol; 2013 Oct; 149(1):32-45. PubMed ID: 23899992
[TBL] [Abstract][Full Text] [Related]
7. The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response.
Hundgeburth LC; Wunsch M; Rovituso D; Recks MS; Addicks K; Lehmann PV; Kuerten S
Clin Immunol; 2013 Mar; 146(3):155-64. PubMed ID: 23352967
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
[TBL] [Abstract][Full Text] [Related]
9. Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes.
Berghmans N; Heremans H; Li S; Martens E; Matthys P; Sorokin L; Van Damme J; Opdenakker G
J Neuroinflammation; 2012 Oct; 9():243. PubMed ID: 23095573
[TBL] [Abstract][Full Text] [Related]
10. Contribution of LTi and T
Schropp V; Rohde J; Rovituso DM; Jabari S; Bharti R; Kuerten S
J Neuroinflammation; 2019 May; 16(1):111. PubMed ID: 31138214
[TBL] [Abstract][Full Text] [Related]
11. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
Hu X; Qin X
Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Interleukin-9 Decreasing Mast Cells Infiltration in Experimental Autoimmune Encephalomyelitis.
Yin JJ; Hu XQ; Mao ZF; Bao J; Qiu W; Lu ZQ; Wu HT; Zhong XN
Chin Med J (Engl); 2017 Apr; 130(8):964-971. PubMed ID: 28397727
[TBL] [Abstract][Full Text] [Related]
14. Oxidative damage and chemokine production dominate days before immune cell infiltration and EAE disease debut.
Hasseldam H; Rasmussen RS; Johansen FF
J Neuroinflammation; 2016 Sep; 13(1):246. PubMed ID: 27630002
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
17. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
[TBL] [Abstract][Full Text] [Related]
18. Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
Quast I; Keller CW; Weber P; Schneider C; von Gunten S; Lünemann JD
J Neuroinflammation; 2016 Feb; 13():42. PubMed ID: 26893156
[TBL] [Abstract][Full Text] [Related]
19. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
20. Decreased CNS inflammation and absence of clinical exacerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis.
al-Sabbagh AM; Goad EP; Weiner HL; Nelson PA
J Neurosci Res; 1996 Aug; 45(4):424-9. PubMed ID: 8872902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
